`
`NAME
`Atanackovic, Djordje
`EDUCATION/TRAINING
`
`INSTITUTION AND LOCATION
`University of Hamburg, Germany
`University of Hamburg, Germany
`Ludwig Institute for Cancer Research,
`New York
`Free University Berlin, Germany
`University Medical Center Hamburg-
`Eppendorf, Germany
`
`BIOGRAPHICAL SKETCH
`POSITION TITLE
`Associate Professor
`
`DEGREE
`Board certification
`Board certification
`
`MM/YY
`08/2010
`04/2009
`
`FIELD OF STUDY
`Hematology/Oncology
`Internal Medicine
`
`Postdoctoral
`
`2000-2003 Tumor Immunology
`
`M.D.
`
`2000
`
`Medicine
`
`Residency
`
`1999-2000
`
`Internal Medicine
`
`A. Personal Statement
`I have a long-standing clinical and research interest in hematologic malignancies, specifically
`plasma cell dyscrasias such as multiple myeloma. In addition, I have a broad background in tumor
`immunology and immunotherapy as well as the biology and pathophysiology of multiple myeloma.
`As a postdoctoral fellow at the Ludwig Institute for Cancer Research at Memorial Sloan-Kettering
`Cancer Center in New York City, I carried out research in tumor immunology focusing on a certain
`group of tumor-specific proteins, so-called cancer-testis antigens, as potential targets for T cell-
`based immunotherapies. After I had returned to the University Medical Center Hamburg-Eppendorf
`in Germany and had founded a translational tumor immunology research group, I decided to focus
`my research on the development of immunotherapeutic approaches for patients with multiple
`myeloma. My group worked on the identification of potential target structures for immunotherapies,
`the evaluation of the biological function of the given proteins, the analysis of spontaneous anti-
`tumor immune responses in myeloma patients, and the development of cellular and antibody-
`based approaches for patients suffering from this hematologic malignancy. I have been PI on
`several grants funded by the German equivalent of the NIH and I successfully managed all the
`different projects (e.g. staffing, research protections, budget), collaborated with researchers
`around the world, produced a large number of peer-reviewed publications, and have introduced
`several of our immunotherapeutic approaches into the clinic. I have been PI in multiple clinical
`trials
`in different human malignancies with a
`focus on multiple myeloma and cancer
`immunotherapy.
`B. Positions and Honors
`Positions and Employment
`Since 01/2014 Director of the Multiple Myeloma Program and of Cancer Immunotherapy,
`University of Utah/Huntsman Cancer Institute
`Attending Physician, Department of Oncology/Hematology/Stem Cell
`Transplantation, University Medical Center Hamburg-Eppendorf
`Head of the Laboratory for Tumor Immunology, Department of
`Oncology/Hematology, University Medical Center Hamburg-Eppendorf, Hamburg,
`Germany
`Clinical and Research Fellow, Department of Oncology/Hematology/Stem Cell
`Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg,
`Germany
`
`2010-2013
`
`2003-2013
`
`2003-2010
`
`Awards
`11/2012 Science Award of the Hamburg Cancer Society
`09/2012 Clinical Science Award of the German Society for Immune and Targeted Therapy
`09/2009 Research Award of the Hubertus Wald Foundation
`1
`
`  
`
`Coalition for Affordable Drugs IV LLC – Exhibit 1022
`
`

`
`11/2007 Research Award of the Foundation for Research on Head and Neck Cancer
`02/2007
`Investigator Award of the Cancer Research Institute (CRI)
`06/2007 Dr. Martini Award
`06/2004 Poster prize of the European Conference on Psychosomatic Research
`Honors
`2006-2007 Stipend of the University of Hamburg for “excellent young researchers”.
`2002-2003 Stipend of the Cancer Research Institute (CRI)
`2000-2002 Stipend of the Deutsche Krebshilfe (German Cancer Aid)
`Other Experience and Professional Memberships
`Member, American Society of Hematology (ASH)
`Member, European Hematology Asscociation (EHA)
`Member, American Society of Clinical Oncology (ASCO)
`Member, American Association for Cancer Research (AACR)
`Member, European Association for Cancer Research (EACR)
`Grant Reviewer, European Commission (6th and 7th Framework Programme, Horizon 2020
`Programme)
`Grant Reviewer, Leukemia & Lymphoma Research U.K.
`Grant Reviewer, Cancer Research UK
`Grant Reviewer, FWF, Austria
`Grant Reviewer, Deutsche Krebshilfe (German Cancer Aid)
`Grant Reviewer, Research Foundation Flanders, Belgium
`Grant Reviewer, Catalan Agency for Health Information, Spain
`Grant Reviewer, Italian Ministry of Health
`Editor, BMC Cancer
`Representative of the Huntsman Cancer Institute on the NCCN Multiple Myeloma Panel
`Patents / Patent Applications
`• U.S. Patent application 12/716481: “IL-16 as a target for the diagnosis and therapy of
`haematological malignancies and solid tumors”.
`• U.S. Patent 8524240: “Diagnosis and therapy of hematological malignancies”.
`• U.S. Patent 20080139464: “Isolated NY-ESO-1 peptides which bind to HLA class II molecules
`and uses thereof”.
`• U.S. Patent 7803382: “Colon cancer antigen panel - The invention provides methods,
`compositions and kits for inducing and/or enhancing an immune response in a subject”.
`Clinical Studies (selection out of 23 studies performed as Principal Investigator)
`Since 2014 A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple
`Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984)
`Against CD38 In Patients with Selected CD38+ Hematological Malignancies.
`Since 2014 A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With
`Advanced Multiple Myeloma.
`A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line
`therapy with or without TG4010 immunotherapy product in patients with stage IV non-
`small cell lung cancer (NSCLC).
`Randomized, multicenter, double-blind, phase 3 trial comparing the efficacy of
`ipilimumab plus etoposide/platinum versus etoposide/platinum in subjects with newly
`diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
`2011-2013 Open label, randomized multi-center phase II study evaluating the efficacy and safety
`of Paclitaxel/Carboplatin with and without Cetuximab as first-line treatment of adeno-
`and undifferentiated CUP (PACET-CUP).
`2011-2012 Randomized, placebo-controlled, double-blind phase 1b/2 study of U3-1287 (AMG
`888) in combination with erlotinib in EGFR treatment naïve subjects with advanced
`Non-Small Cell Lung Cancer (NSCLC) who have progressed on at least one prior
`chemotherapy.
`
`2013
`
`2
`
`2013
`
`  
`
`

`
`2011-2012 Open-label, randomized, controlled, multicenter Phase II study investigating cilengitide
`in combination with cetuximab and platinum-based chemotherapy (cisplatin/vinorelbine
`or cisplatin/gemcitabine) compared to cetuximab and platinum-based chemotherapy
`alone as first-line treatment for patients with advanced NSCLC (CERTO).
`2010-2011 A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-
`line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring
`an EGFR activating mutation (LUX-Lung 3).
`2010-2013 Double-blind, placebo-controlled, randomized phase II study investigating the efficacy
`of Bevacizumab for symptom-control in patients with malignant ascites due to
`advanced-stage-gastrointestinal cancers (AIO-SUP-0108).
`2009-2011 Safety and efficacy phase I/IIa trial of an RNActive-derived cancer vaccine in stage
`IIIB/IV non small cell lung cancer (CV-9201-003 NSCLC).
`2009-2013 An open-label, randomized, controlled, multi-center, Phase II trial investigating 2 EMD
`525797 doses in combination with cetuximab+irinotecan versus cetuximab+irinotecan
`alone, as second-line treatment for subjects with k-ras wild type (WT) metastatic
`colorectal cancer (POSEIDON).
`2008-2009 Analysis of the expression of a specific set of genes and tumor antigens in patients
`with non-small cell lung cancer or melanoma (ONCO RD-001).
`2008-2009 Phase II, randomized, open label, multicenter study of intradermal IMA901 plus GM-
`CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell
`carcinoma patients with measurable disease (IMA901-202).
`2007-2012 A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy
`of recMAGE-A3+AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant
`therapy in patients with respectable MAGE-A3-positive Non-Small Cell Lung Cancer
`(MAGRIT).
`2007-2013 A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15
`cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant
`chemo(-radio)therapy, to patients with MAGE-A3-positive Non-Small Cell Lung cancer
`(stage IB, II, or III)” (MAGE-A3-AS15-NSC-001).
`Sole immunization with NY-ESO-1 protein in comparison to immunization with NY-
`ESO-1 protein in combination with sodium urate crystals as an adjuvant in patients
`with head and neck cancer after R0 resection: An early, randomized phase II study.
`C. Selected Peer-reviewed Publications (Selected from 80 peer-reviewed publications)
`1. Yousef, S., Marvin, J., Steinbach, M., Langemo, A., Kovacsovics, T., Binder, M., Kröger, N.,
`Luetkens, T., Atanackovic, D. (2015) Immunomodulatory molecule PD-L1 is expressed on
`malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of
`multiple myeloma patients. Blood Cancer Journal 5: e285
`2. Luetkens, T., Kobold, S., Cao, Y., Ristic, M., Schilling, G., Tams, S., Bartels, B.M., Templin, J.,
`Bartels, K., Hildebrandt, Y., Yousef, S., Marx, A., Haag, F., Bokemeyer, C., Kröger, N.,
`Atanackovic, D. (2014) Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple
`myeloma patients after allogeneic stem cell
`transplantation. Cancer
`Immunology
`Immunotherapy 63: 1151-1162
`3. Reinhard, H., Yousef, S., Luetkens, T., Fehse, B., Berdien, B., Kröger, N., Atanackovic, D.
`(2014) Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell
`responses in multiple myeloma patients. Blood Cancer Journal 4: e212
`4. Berdien, B., Mock, U., Atanackovic, D., Fehse, B. (2014) TALEN-mediated editing of
`endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral
`gene transfer. Gene Therapy 21: 539-548
`5. Atanackovic, D., Luetkens, T., Kröger, N. (2013) Coinhibitory molecule PD-1 as a potential
`target for the immunotherapy of multiple myeloma. Leukemia 28: 993-100
`6. Atanackovic, D., Schilling, G. (2013) Second autologous transplant as salvage therapy in
`multiple myeloma. British Journal of Haematology 163: 565-572
`
`2004
`
`  
`
`3
`
`

`
`7. Nuber, N., Curioni-Fontecedro, A., Dannenmann, S.R., Matter, C., von Boehmer, L.,
`Atanackovic, D., Knuth, A., van den Broek, M. (2013) MAGE-C1/CT7 spontaneously triggers
`a CD4(+) T-cell response in multiple myeloma patients. Leukemia 27: 1767-1769
`8. Berdien, B., Reinhard, H., Meyer, S., Spöck, S., Kröger, N., Atanackovic, D., Fehse, B. (2013)
`Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
`Human Vaccines & Immunotherapeutics 9: 1205-1216
`9. Atanackovic, D., Hildebrandt, Y., Templin, J., Cao, Y., Keller, C., Panse, J., Meyer, S.,
`Reinhard, H., Bartels, K., Lajmi, N., Sezer, O., Zander, A.R., Marx, A.H., Uhlig, R., Zustin, J.,
`Bokemeyer, C., Kröger, N. (2012) Role of interleukin 16 in multiple myeloma. Journal of the
`National Cancer Institute 104: 1005-1020
`10. Atanackovic, D., Panse, J., Hildebrandt, Y., Jadczak, A., Kobold, S., Cao, Y., Templin, J.,
`Meyer, S., Reinhard, H., Bartels, K., Lajmi, N., Zander, A.R., Marx, A.H., Luetkens, T.,
`Bokemeyer, C., Kroger, N. (2011) Surface molecule CD229 as a novel target for the diagnosis
`and treatment of multiple myeloma. Haematologica 96: 1512-1520
`11. Atanackovic, D., Hildebrandt, Y., Jadczak, A., Cao, Y., Luetkens, T., Meyer, S., Kobold, S.,
`Bartels, K., Pabst, C., Lajmi, N., Gordic, M., Stahl, T., Zander, A.R., Bokemeyer, C., Kröger; N.
`(2010) Cancer-testis antgens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple
`myeloma cells. Haematologica 95:785-793
`12. Atanackovic, D., Luetkens, T., Hildebrandt, Y., Arfsten, J., Bartels, K., Horn, C., Stahl, T.,
`Cao, Y., Zander, A.R., Bokemeyer, C., Kroger, N. (2009) Longitudinal analysis and prognostic
`impact of cancer-testis antigen expression in multiple myeloma. Clinical Cancer Research
`15:1343-1352
`13. Atanackovic, D., Cao, Y., Luetkens, T., Panse, J., Faltz, C., Arfsten, J., Bartels, K., Wolschke,
`C., Eiermann, T., Zander, A.R., Fehse, B., Bokemeyer, C., Kroger, N.
`(2008)
`CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of
`patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica
`93:419-426
`14. Atanackovic, D., Altorki, N.K., Cao, Y., Ritter, E., Ferrara, C., Ritter, G., Hoffman, E.W.,
`Bokemeyer, C., Old, L.J., Gnjatic, S. (2008) Booster vaccination of cancer patients with
`MAGE-A3 protein reveals long-term immunological memory or tolerance depending on
`priming. Proceedings of the National Acadamy of Sciences USA 105:1650–1655
`15. Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G.,
`Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D.K., Zander, A.R.,
`Old, L.J., Bokemeyer, C., Kröger, N. (2007) Cancer-testis antigens are commonly expressed in
`multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
`Blood 109:1103-1112
`16. Atanackovic, D., Block, A., de Weerth, A., Faltz, C., Hossfeld, D.K., Hegewisch-Becker, S.
`(2004) Characterization of effusion-infiltrating T cells: benign versus malignant effusions.
`Clinical Cancer Research 10:2600-2608
`17. Atanackovic, D., Altorki, N.K., Stockert, E., Williamson, B., Jungbluth, A., Ritter, E., Santiago,
`D., Ferrara, C.A., Matsuo, M., Selvakumar, A., Dupont, B., Chen, Y.T., Hoffman, E.W., Ritter,
`G., Old, L.J., Gnjatic, S. (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in
`lung cancer patients. Journal of Immunology 172:3289-3296
`18. Gnjatic, S., Atanackovic, D., Jager, E., Matsuo, M., Selvakumar, A., Altorki, N.K., Maki, R.G.,
`Dupont, B., Ritter, G., Chen, Y.T., Knuth, A., Old, L.J. (2003) Survey of naturally occuring
`CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody
`responses. Proceedings of the National Academy of Sciences USA 100:8862-8867
`
`
`D. Research Support
`01/2014-12/2016 Institutional support in the form of a start-up grant totaling $275,000/year for
`three years.
`
`  
`  
`
`4